- Home
- NUVB vs RA Comparison
NUVB vs RA Comparison
Compare NUVB & RA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVB
- RA
- Stock Information
- Founded
- NUVB 2018
- RA 2016
- Country
- NUVB United States
- RA United States
- Employees
- NUVB N/A
- RA 1260
- Industry
- NUVB Biotechnology: Pharmaceutical Preparations
- RA Investment Managers
- Sector
- NUVB Health Care
- RA Finance
- Exchange
- NUVB Nasdaq
- RA Nasdaq
- Market Cap
- NUVB 679.9M
- RA 711.7M
- IPO Year
- NUVB N/A
- RA N/A
- Fundamental
- Price
- NUVB $2.50
- RA $13.25
- Analyst Decision
- NUVB Strong Buy
- RA
- Analyst Count
- NUVB 6
- RA 0
- Target Price
- NUVB $7.83
- RA N/A
- AVG Volume (30 Days)
- NUVB 5.9M
- RA 280.8K
- Earning Date
- NUVB 08-04-2025
- RA 01-01-0001
- Dividend Yield
- NUVB N/A
- RA 14.73%
- EPS Growth
- NUVB N/A
- RA N/A
- EPS
- NUVB N/A
- RA N/A
- Revenue
- NUVB $10,957,000.00
- RA N/A
- Revenue This Year
- NUVB $98.78
- RA N/A
- Revenue Next Year
- NUVB $489.71
- RA N/A
- P/E Ratio
- NUVB N/A
- RA N/A
- Revenue Growth
- NUVB N/A
- RA N/A
- 52 Week Low
- NUVB $1.54
- RA $11.89
- 52 Week High
- NUVB $3.97
- RA $17.32
- Technical
- Relative Strength Index (RSI)
- NUVB 63.18
- RA 51.75
- Support Level
- NUVB $2.06
- RA $13.18
- Resistance Level
- NUVB $2.62
- RA $13.29
- Average True Range (ATR)
- NUVB 0.15
- RA 0.09
- MACD
- NUVB 0.04
- RA -0.03
- Stochastic Oscillator
- NUVB 78.71
- RA 35.53
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).
About RA Brookfield Real Assets Income Fund Inc.
Brookfield Real Assets Income Fund Inc. is a diversified, closed-end management investment company. Its investment objective is to seek a high total return, through high current income and secondarily, through the growth of capital. The Fund seeks to achieve its investment objective by investing in the real asset class, which includes the following: Real Estate Securities; Infrastructure Securities; and Natural Resources Securities. The Firm manages separate accounts, registered funds, and opportunistic strategies for institutional and individual clients, including financial institutions, public and private pension plans, insurance companies, endowments and foundations, sovereign wealth funds, and high-net-worth investors.